Evonik's Independence Test: Oddo's 19-Euro Marker Replaces a 24-Euro Bid
Published on 11/22/2026 at 08:01 | Editorial boerse-global.deEvonik's investors are being asked to answer a question the company never had to face while BASF was circling it: what is the chemicals maker worth on its own merits? Oddo BHF supplied an early verdict on Friday, cutting the stock from "Outperform" to "Neutral" and trimming its price target to €19 from €22. That is a lower yardstick, though not yet a judgment on what Evonik can achieve unaided.
The reassessment lands two days after BASF walked away from its takeover ambitions. The Ludwigshafen giant pulled the plug on Thursday following Evonik's rejection of two unsolicited all-cash proposals, the last of which stood at €24 per share. BASF had weighed a further moderate increase but concluded a richer price was not in the interests of its own shareholders. Shares in Evonik fell 16% on Thursday, according to Reuters, and closed Friday at €18.18 — below Oddo's freshly lowered target.
Price Was Never the Sticking Point
The deal did not collapse over money alone. Handelsblatt reported Thursday that Evonik harbored fundamental doubts about whether BASF would be the better owner, and that neither a higher offer nor guarantees on sites and jobs could have dissolved that resistance. Reuters had reported as much on 18 November, citing two people close to Evonik: a sweeter bid on its own would not have been enough to win backing, and a convincing industrial rationale was needed too.
That distinction matters for anyone treating the abandoned €24 proposal as a floor under the stock. It offers no reliable downside protection, because the bid was never a pure valuation exercise in the first place.
Should investors sell immediately? Or is it worth buying Evonik?
Rettig's Clean Slate
Interim chief executive Claus Rettig framed the withdrawal as a liberation of sorts. Speaking to Reuters on Thursday, he said BASF's exit removed an uncertainty hanging over the workforce and allows Evonik to concentrate fully on developing under its own steam. For shareholders, the pertinent issue is whether that freedom translates into better earnings prospects. A sharper focus on the existing business describes a direction, not an outcome.
Labor Wants Commitments
The IG BCE union is not treating the episode as closed. According to Handelsblatt, it demanded on Friday fresh pledges covering investment, employment, apprenticeships and site security. Those calls add a second audience — beyond the equity market — that Evonik's management will have to satisfy as it charts a solo course.
The Anchor Holder Stays the Course
Evonik's largest shareholder sees no reason to alter its plans. The RAG-Stiftung said Friday, per Reuters, that it still intends to gradually reduce its stake to 25.1%. The foundation's timetable thus proceeds independently of whether a suitor is at the door.
Evonik at a turning point? This analysis reveals what investors need to know now.
Earnings Guidance Becomes the Real Scorecard
What would justify a higher multiple from here is concrete evidence of operational progress — the kind of demonstrable improvement that lets investors credit Evonik with stronger results without the cushion of a bid. The positive case rests on management making that link legible; the more specific the proof, the more plausible a re-rating becomes.
The mirror risk is grimmer than simply missing a positive catalyst. Should earnings prospects deteriorate, holders would have to mark down their assumptions about Evonik's standalone value. Until operating advances are documented, headroom for a richer valuation remains largely hypothetical, and the gap to any single analyst's target will matter less than the direction of the next earnings forecast. That guidance — new or updated — is the nearest real test of whether the standalone story holds.
Ad
Evonik Stock: New Analysis - 22 November
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
